Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain AMGN message board posts where the ticker symbol AMGN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest AMGN SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-034510 Size: 4 KB
2017-12-12
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001127602-17-034509 Size: 4 KB
2017-12-12
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010277 (34 Act)  Size: 14 KB
2017-12-04 000-12477
171236095
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-032117 Size: 4 KB
2017-11-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-031636 Size: 5 KB
2017-11-08
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-17-331065 (34 Act)  Size: 280 KB
2017-11-02 001-37702
171172773
424B2  Documents Prospectus [Rule 424(b)(2)]
Acc-no: 0001193125-17-329643 (33 Act)  Size: 522 KB
2017-11-01 333-216060
171169819
FWP  Documents Filing under Securities Act Rules 163/433 of free writing prospectuses
Acc-no: 0001193125-17-327315 (34 Act)  Size: 15 KB
2017-10-31 333-216060
171166196
424B3  Documents Prospectus [Rule 424(b)(3)]
Acc-no: 0001193125-17-326003 (33 Act)  Size: 508 KB
2017-10-31 333-216060
171164156
8-K  Documents Current report, item 1.02
Acc-no: 0001193125-17-325797 (34 Act)  Size: 18 KB
2017-10-31 001-37702
171163956
More AMGN SEC Filings


Related news from
Mon, 18 Dec 2017
20:21:56 +0000
Gilead Sciences’ Valuation in December 2017
Gilead Sciences (GILD), a leading biopharmaceutical company headquartered in California, is involved in discovering, developing, and commercializing various innovative medicines.
Mon, 18 Dec 2017
20:00:24 +0000
10 More Retirement Stocks to Buy and Hold for the Rest of Your Life
In September, we highlighted 10 retirement stocks to buy and hold for the rest of your life. The above-market returns Buffett and partner Charlie Munger had provided for decades seemed to have come to an end.
Mon, 18 Dec 2017
12:03:00 +0000
The 5 Best-Selling Drugs of 2017
Autoimmune-disease and cancer drugs ruled yet again.
Sun, 17 Dec 2017
13:07:00 +0000
3 Attractive Income Stocks Whose Dividends Could Double
These stocks have great dividends. And they should only get better.
Fri, 15 Dec 2017
18:20:17 +0000
Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Fri, 15 Dec 2017
16:15:00 +0000
Biotech Celgene May Rise 35% In 2018
A peer analysis of biotechnology companies suggests Celgene's stock will climb in 2018.
Fri, 15 Dec 2017
15:33:00 +0000
Amgen: Why Goldman Just Wants to Be Friends
Goldman Sachs is out with an update on healthcare ahead of the new year, and while analyst Jami Rubin and her team still bullish on Amgen (AMGN), she removed it from the firm's Conviction Buy list. Rubin still reiterated a Buy rating on the stock and $218 price target, writing that she believes new products will offset erosion of its legacy biologics, like Neulasta, which is facing increasing competition,  and continue to drive low-single-digit growth.
Fri, 15 Dec 2017
13:04:18 +0000
Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : December 15, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amgen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more <b>(Read more...)</b>
Thu, 14 Dec 2017
21:00:00 +0000
Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D and Operations facility on Dec. 11, 2017.
Wed, 13 Dec 2017
17:25:00 +0000
Amgen: Even Biotech Stocks Boost Their Dividends
Biotech giant Amgen (AMGN) is providing some holiday cheer to investors with a 15% dividend increase. Last year Amgen paid out about one-third of its earnings in dividends. Shares of Amgen have gained 0.3% to $176.79 at 12:20 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.3% to $106.09.
Wed, 13 Dec 2017
13:15:38 +0000
Stocks making the biggest moves premarket: HON, LLY, AMGN, TM, HD & more
These are the stocks posting the largest moves before the bell.
Tue, 12 Dec 2017
21:00:00 +0000
Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 12, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Tue, 12 Dec 2017
19:54:27 +0000
Jim Simons: Pioneer Quant Manager
A brilliant mathematician turned his mind to investing, and emerged a big winner
Mon, 11 Dec 2017
22:35:18 +0000
Amgen's Kyprolis improves overall survival in blood cancer patients
Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer. Kyprolis when used with two standard of care drugs, dexamethasone and Celgene Corp's Revlimid, reduced the risk of death by 21 percent and extended survival by 7.9 months, compared with patients treated with the two drugs alone, the company said. The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib, in multiple myeloma patients whose cancer had relapsed following prior treatment or did not respond to treatment.
Mon, 11 Dec 2017
21:00:00 +0000
KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory ...
Mon, 11 Dec 2017
19:02:54 +0000
Biopharma wins in Trump tax bill
One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.
Mon, 11 Dec 2017
14:00:00 +0000
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to support their immediate relief efforts.
Sun, 10 Dec 2017
17:47:56 +0000
Republican tax bill makes big winners of Amgen, Gilead and other drugmakers
Of all U.S. companies, drugmakers have some of the most cash held outside the country.
Sun, 10 Dec 2017
15:00:00 +0000
Deciphering Wall Street's Differing Views of Amgen
What to make of the divergent views of Amgen's shares.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is the place to be to pick up on new and proven investment ideas." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards